ESTRO 2025 - Abstract Book

S910

Clinical - Haematology

ESTRO 2025

Conclusion: Chemo-immunotherapy with R-CHOP21 regimen followed by response-adapted ISRT is feasible in patients with stage I-II nodal DLBCL in low- and middle-income countries and leads to favorable clinical outcomes and acceptable toxicity profile and QoL.

Keywords: DLBCL, Chemo-immunotherapy, ISRT